title: Immunotherapy for Type 1 diabetes: getting beyond a negative first impression.
authors.forename: Paolo
authors.initials: P
authors.lastname: Pozzilli
authors.forename: Rocky
authors.initials: R
authors.lastname: Strollo
mesh_terms: D000069594:Abatacept; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use; D001324:Autoantigens / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D018834:Chaperonin 60 / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy*; D005968:Glutamate Decarboxylase / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000276:immunology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001324:Autoantigens; D017252:CD3 Complex; D018834:Chaperonin 60; C447781:DiaPep 277; D018796:Immunoconjugates; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D000069594:Abatacept; D005968:Glutamate Decarboxylase; C502540:teplizumab